AGN’s CEO, David Pyott, said on today’s CC that Merz’s delay in launching Xeomin for cosmetic indications is due to a manufacturing glitch. If true, this answers the question I asked in the second-from-bottom paragraph of #msg-65423443.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”